Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-08-03
2001-09-25
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C514S365000
Reexamination Certificate
active
06294559
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
REFERENCE TO MICROFICHE APPENDIX
Not applicable.
FIELD OF THE INVENTION
This invention is directed to ligands that bind to human peroxisome proliferator activated receptors (PPAR) &ggr;1 and &ggr;2. The ligands are useful as antiviral, antiproliferative and antitumor agents
BACKGROUND OF THE INVENTION
This disclosure is directed to ligands that bind to peroxisome proliferator activated receptors (PPAR) &ggr;1 or &ggr;2 and which function as antiproliferative agents. The invention is also directed to the use of PPAR &ggr;1 or &ggr;2 to identify compounds that are antiproliferative agents. This disclosure is further directed to new medical uses of these compounds.
Peroxisome proliferators are a structurally diverse group of compounds that when administered to rodents elicit dramatic increases in the size and number of hepatic and renal peroxisomes, as well as concomitant increases in the capacity of peroxisomes to metabolize fatty acids via increased expression of the enzymes of the beta-oxidation cycle. Compounds of this group include but are not limited to the fibrate class of hyperlipidemic drugs, herbicides and phthalate plasticizers. Peroxisome proliferation is also triggered by dietary or physiological factors such as a high-fat diet and cold acclimatization.
Identification of a member of the nuclear hormone receptor superfamily activated by these chemicals has facilitated analysis of the mechanism by which peroxisome proliferators exert their pleiotropic effects. This receptor, known as peroxisome proliferator activated receptor alpha (PPAR), is activated by a number of medium and long-chain fatty acids. The receptor stimulates expression of genes encoding rat acyl-CoA oxidase and hydratase-dehydrogenase.
The PPAR &ggr; receptor subtypes are involved in activating the program of adipocyte differentiation and are not involved in stimulating peroxisome proliferation in the liver. There are two isoforms of PPAR gamma: PPAR &ggr;1 (PPAR&ggr;1) and PPAR &ggr;2 (PPAR&ggr;2), which differ only in that PPAR&ggr;2 contains an additional 28 amino acids present at the amino terminus. In mice, PPAR&ggr;2 is expressed specifically in fat cells. Tontonoz et al.,
Cell
79: 1147-1156 [1994] provide evidence to show that one physiological role of PPAR&ggr;2 is to induce adipocyte differentiation. As with other members of the nuclear hormone receptor superfamily, PPAR&ggr;2 regulates the expression of genes through interaction with other proteins and binding to hormone response elements for example in the 5′ flanking regions of responsive genes. An example of a PPAR&ggr;2 responsive gene is the tissue-specific adipocyte P2 gene.
Three classes of ligands have been identified for the PPAR&ggr; receptors. Prostaglandin J
2
could represent an endogenous class of ligands (Forman et al.
Cell
83: 803-812 [1995], Kliewer et al.
Cell
83: 813-819 [1995]), while the thiazolidinediones could represent another class (Lehman et al.
J. Biol. Chem
270: 12953-12956 [1995]). A third class of ligands is represented by a new series of MRL compounds. The thiazolidinediones and MRL compounds are antidiabetic compounds effective in reducing glucose, lipid and insulin levels in rodent models. Thus, novel PPAR&ggr; ligands and regulators could be used in the treatment of diabetes and effect fat cell differentiation. In addition, cyclopentanone prostaglandins having structural similarity to Prostaglandin J2 have been described to have antiproliferative and antiviral properties (C. Rozera et al., J. Clin. Invest. 97:1795-1803; M. Santoro et al., J. Gen. Virol. 68:1153-1158; Sasaki and Fukushima, Anti-Cancer Drugs 5:131-138). Other compounds of this class of prostaglandins but the bind to PPAR &ggr; receptor subtypes will also have antiproliferative and antivral properties.
SUMMARY OF THE INVENTION
This invention is directed to compounds and ligands that bind to peroxisome proliferator activated receptors (PPAR) &ggr;1 and &ggr;2 and which function as antiproliferative, antiviral and antitumor agents. The invention is also directed to the use of PPAR &ggr;1 and &ggr;2 to identify compounds that are antiproliferative, antiviral or antitumor agents. (The invention is further directed to the medical use of the antiproliferative, antiviral and antitumor agents.)
REFERENCES:
patent: 5594015 (1997-01-01), Kuntz et al.
patent: 0177353 (1986-04-01), None
Zhu, et al., “Cloning of a New Member of the Peroxisome Proliferator-activated Receptor Gene . . . ”, J. of Biol. Chem., vol. 268, No. 36, pp. 26817-26820, Dec. 25, 1993.
Greene, et al., “Isolation of the Human Peroxisome Proliferator Activated Receptor Gamma cDNA: Expression . . . ”, Gene Expression, vol. 4, pp. 281-2999, 1993.
Tontonoz, et al., “Stimulation of Adipogenesis in Fibroblasts by PPARy2, a Lipid-Activated Transcription Factor”, Cell, vol. 79, pp. 1147-1156, Dec. 30, 1994.
Forman, et al., “15-Deoxy— 12,14-Prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPARy”, Cell, vol. 83, pp. 803-812, Dec. 1, 1995.
Kliewer, et al., “A Prostaglandin J2 Metabolite Binds Peroxisome Proliferator-Activated Receptor y and Promotes . . . ”, Cell, vol. 83, pp. 813-819, Dec. 1, 1995.
Lehmann, et al., “An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator . . . ”, J. of Biol. Chem., vol. 270, No. 22, pp. 12953-12956, Jun. 2, 1995.
Elbrecht, et al., “Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator . . . ”, Biochem. and Biophys. Res. Comm., vol. 224, pp. 431-437, 1996.
Santoro, et al., “PGJ2, A New Antiviral Prostaglandin: Inhibition of Sendai Virus Replication and Alteration . . . ”, J. Gen. Virol., vol. 68, pp. 1153-1158, 1987.
Dreyer, et al., “Control of the Peroxisomal B-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors”, Cell, vol. 68, pp. 879-887, Mar. 6, 1992.
Chen, et al., “Identification of Two mPPAR Related Receptors and Evidence for the Existence . . . ”, Biochem. and Biophys. Res. Comm., vol. 196, No. 2, pp. 671-677, Oct. 29, 1993.
Kliewer, et al., “Differential expression and activation of a family of murine peroxisome proliferator . . . ”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 7355-7359, Jul. 1994.
Tontonoz, et al., “mPPARy: tissue-specific regulator of an adipocyte enhancer”, Genes & Development, vol. 8, pp. 1224-1234, 1994.
Zhu, et al., “Structural organization of mouse peroxisome proliferator-activated receptor y (mPPARy) gene . . .”, Proc. Natl. Adac. Sci. USA, vol. 92, pp. 7921-7925, Aug. 1995.
Aperlo, et al., “cDNA cloning and characterization of the transcriptional activties of the hamster peroxisome . . . ”, Gene, vol. 162, pp. 297-302, 1995.
Duvic et al 111CA:225334, 1988.*
Hughes-Fulford, et al., “Inhibition of DNA Synthesis and Cell Cycle by Prostaglandins Independent of Cyclic AMP”, Advances in Prostaglandin, Thromboxanee and Leukotriene Research, vol. 15, pp. 401-404, 1985.
Lacal, et al., “Effects of Cyclopentenone Prostaglandins on Myeloid Cells during Early Infection with HTLV-1.II. Regulation of Synthesis of Inducible p72 Heat Shock Protein”, Journal of Pharmacology and Experimental Therapeutics, vol. 271, No. 2, pp. 10096-1102, 1994.
Mueller, et al., “Terminal Differentiation of Human Breast Cancer through PPAR&ggr;”, Molecular Cell, vol. 1, pp. 465-470, Feb. 1998.
Narumiya, et al., “Site and Mechanism of Growth Inhibition by Prostaglandins. I. Active Transport and Intracellular Accumulation of Cyclopentenone Prostaglandins . . . ”, Journal of Pharmacol. and Exp. Therap., vol. 239, No. 2, pp. 500-505, 1986.
Narumiya, et al., “Site and Mechanism of Growth Inhibition by Prostaglandins. II. Temperature-Dependent Transfer of a Cyclopentenone Prostaglandin to Nuclei”, Journal of Pharmacol. and Exp Therap., vol. 239, No. 2, pp. 506-511, 1986.
Rozera, et al., “Inhibition of HIV-1 Replication by Cyclopentenone Prostaglandins in Acutely Infected Human Cells”, J. Clin. Invest., vol. 97, No. 8
Coppola Joseph A.
Merck & Co. , Inc.
Travers Russell
Tribble Jack L.
LandOfFree
Antiproliferative agents associated with peroxisome... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiproliferative agents associated with peroxisome..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiproliferative agents associated with peroxisome... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2461960